Spots Global Cancer Trial Database for Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Official Title: Single Arm Dose-Escalation Trial of Fructo-Oligosaccharides in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Study ID: NCT02805075

Conditions

Hematopoietic and Lymphoid Cell Neoplasm

Recurrent Hematologic Malignancy

Interventions

Fructooligosaccharide

Laboratory Biomarker Analysis

Study Description

Brief Summary: This pilot phase I trial studies the side effects and best dose of fructooligosaccharides in treating patients with blood cancer who are undergoing donor stem cell transplant. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Nutritional supplements such as fructooligosaccharides may reduce the incidence of graft-versus-host disease in patients with blood cancer undergoing donor stem cell transplant.

Detailed Description: PRIMARY OBJECTIVES: I. Conduct a dose escalation trial to determine the tolerability of the fructo-oligosaccharides prebiotic in allogeneic hematopoeitic stem cell transplant (HSCT) patients. OUTLINE: This is a dose escalation study. Patients receive fructooligosaccharides (FOS) orally (PO) twice daily (BID) for 21 days starting at 7 days before allogeneic hematopoietic stem cell transplant in the absence of disease progression or unexpected toxicity. After completion of study treatment, patients are followed for 100 days.